Catalyst overview
Research summary
This catalyst tracks a Phase 1b initiation for CLR 121125 in Triple-negative breast cancer. The expected timing is based on the latest available company guidance and may change.
05/14/26:- First patients dosed; dosimetry, safety and efficacy updates expected Q2 and Mid-2026. 08/13/26:- Phase 1b triple-negative breast cancer trial enrollment began and first patients were dosed.
Verification
Confirm timing and program details against the company announcement or filing.